Deven Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2300 in its research report dated September 02, 2025.
ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1570 in its research report dated August 19, 2025.
Stocks to Watch, 18 August: Stocks like Glenmark Pharma, Inox Wind, Zaggle Prepaid Ocean Services, Easy Trip Planners, KEC International, EMS, Torrent Power, JK Cement, Globe Civil Projects, Indian Bank, ICICI Bank, ONGC, and Tata Power will be in focus on August 18.
ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1620 in its research report dated July 18, 2025.
Stocks to Watch, 11 July: Stocks like Tata Consultancy Services, Tata Elxsi, Anand Rathi Wealth, Indian Renewable Energy Development Agency IREDA, Hindustan Unilever, Glenmark Pharma, Aegis Logistics, and Meta Infotech will be in focus on July 11.
Stocks to Watch, 06 May: Stocks like Computer Age Management Services, Bombay Dyeing & Manufacturing Company, Zee Media Corporation, Jammu & Kashmir Bank, Prataap Snacks, Hind Rectifiers, Cigniti Technologies, Coforge, Indian Energy Exchange, Paras Defence and Space Technologies, and IRCON International will be in focus on May 6.
Stocks to Watch, 17 Apr: Stocks like Waaree Renewable Technologies, GTPL Hathway, Prestige Estates Projects, UltraTech Cement, Bharat Heavy Electricals, Indian Railway Finance Corporation, SML Isuzu, Petronet LNG, SBI Cards and Payment Services, Glenmark Pharmaceuticals, Tata Steel, Ballarpur Industries, and Karnataka Bank will be in focus on April 17.
The US FDA however noted that the recall was a voluntary one, issued by the firm itself on March 13 this year.
Stocks to Watch, Mar 21: Stocks like Lloyds Metals and Energy, Ashoka Buildcon, CG Power and Industrial Solutions, Unichem Laboratories, Happiest Minds Technologies, Piramal Pharma, Power Finance Corporation, Asian Paints, Container Corporation of India, Tamilnad Mercantile Bank, and Endurance Technologies will be in focus on March 21.
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1768 in its research report dated February 18, 2025.
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1894 in its research report dated November 18, 2024.
Dreamfolks Services, Sterling and Wilson Renewable Energy, Ugro Capital, Aster DM Healthcare, ONGC, Ramco Cements, Tata Steel, Avalon Technologies, and HDFC Bank will also be in focus on September 23.
The market may consolidate before showing further upward movement in the coming sessions. Below are some trading ideas for the near term.
ICICI Securities recommended reduce rating on Glenmark Pharmaceuticals with a target price of Rs 1345 in its research report dated August 16, 2024.
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1894 in its research report dated August 20, 2024.
Relicab Cable Manufacturing, Shanti Educational Initiatives, Kiri Industries, Tata Steel, Hinduja Global Solutions, and Polyplex Corporation will also be in focus on August 16.
Glenmark Pharmaceuticals Share Price | Glenmark’s current portfolio consists of 198 products authorized for distribution in the US market place and 50 ANDA’s pending approval with the US FDA.
L&T Finance, Network18 Media and Investments, TV18 Broadcast, Alok Industries, and KEC International will also be in focus on Thursday.
The company has received approval from the US Food and Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets (250 mg/125 mg), the Mumbai-based drug maker said in a statement.
Glenmark Pharmaceuticals Share Price | The share touched a 52-week high of Rs 1,095.95 and a 52-week low of Rs 516.65 on 25 April, 2024 and 26 April, 2023, respectively.
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1266 in its research report dated April 05, 2024.
KR Choksey recommended Accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 984 in its research report dated February 22, 2024.
Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70 percent
Glenmark Pharma hit the highest level since 2017. The stock has formed long bullish candlestick pattern on the daily timeframe with strong volumes, and traded above all key moving averages.
Glenmark Pharma was the biggest gainer not only in the Nifty500 index but also amongst F&O stocks. The stock has formed strong bullish candlestick pattern on the daily scale, with trading above all key moving averages.